SWELL1 regulates skeletal muscle cell size, intracellular signalling, adiposity and glucose metabolism

  1. Ashutosh Kumar
  2. Litao Xie
  3. Chau My Ta
  4. Antentor J Hinton
  5. Susheel K Gunasekar
  6. Rachel A Minerath
  7. Karen Shen
  8. Joshua M Maurer
  9. Chad E Grueter
  10. E Dale Abel
  11. Gretchen Meyer
  12. Rajan Sah  Is a corresponding author
  1. Washington University, United States
  2. Washington University School of Medicine, United States
  3. University of Iowa, United States

Abstract

Maintenance of skeletal muscle is beneficial in obesity and Type 2 diabetes. Mechanical stimulation can regulate skeletal muscle differentiation, growth and metabolism, however the molecular mechanosensor remains unknown. Here, we show that SWELL1 (Lrrc8a) functionally encodes a swell-activated anion channel that regulates PI3K-AKT, ERK1/2, mTOR signaling, muscle differentiation, myoblast fusion, cellular oxygen consumption, and glycolysis in skeletal muscle cells. LRRC8A over-expression in Lrrc8a KO myotubes boosts PI3K-AKT-mTOR signaling to supra-normal levels and fully rescues myotube formation. Skeletal muscle targeted Lrrc8a KO mice have smaller myofibers, generate less force ex vivo, and exhibit reduced exercise endurance, associated with increased adiposity under basal conditions, and glucose intolerance and insulin resistance when raised on a high-fat diet, compared to WT mice. These results reveal that the LRRC8 complex regulates insulin-PI3K-AKT-mTOR signalling in skeletal muscle to influence skeletal muscle differentiation in vitro and skeletal myofiber size, muscle function, adiposity and systemic metabolism in vivo.

Data availability

We have uploaded the RNA sequencing data file in GEO (accession code: Series GSE156667 )

The following data sets were generated

Article and author information

Author details

  1. Ashutosh Kumar

    Department of Internal Medicine, Cardiovascular Division, Washington University, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Litao Xie

    Department of Internal Medicine, Cardiovascular Division, Washington University, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Chau My Ta

    Department of Internal Medicine, Cardiovascular Division, Washington University School of Medicine, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Antentor J Hinton

    Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa city, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Susheel K Gunasekar

    Department of Internal Medicine, Cardiovascular Division, Washington University, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Rachel A Minerath

    Fraternal Order of Eagles Diabetes Research Center, Division of Cardiology, University of Iowa, Iowa city, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Karen Shen

    Program in Physical Therapy and Departments of Neurology, Biomedical Engineering and Orthopedic Surgery, Washington University, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Joshua M Maurer

    Department of Internal Medicine, Cardiovascular Division, Washington University, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Chad E Grueter

    Fraternal Order of Eagles Diabetes Research Center,Division of Cardiology, University of Iowa, Iowa city, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. E Dale Abel

    Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, University of Iowa, Iowa City, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5290-0738
  11. Gretchen Meyer

    Program in Physical Therapy and Departments of Neurology, Biomedical Engineering and Orthopedic Surgery, Washington University, St. Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Rajan Sah

    Department of Internal Medicine, Cardiovascular Division, Washington University School of Medicine, St. Louis, United States
    For correspondence
    rajan.sah@wustl.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1092-1244

Funding

National Institutes of Health (1R01DK106009)

  • Rajan Sah

National Institutes of Health (R01HL125436)

  • Chad E Grueter

National Institutes of Health (RO1HL127764)

  • E Dale Abel

National Institutes of Health (RO1HL112413)

  • E Dale Abel

National Institutes of Health (1P30AR074992-01)

  • Rajan Sah

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to the approved institutional animal care and use committee (IACUC) protocols of Washington University in St. Louis (20180217) and the University of Iowa (1308148).

Copyright

© 2020, Kumar et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,058
    views
  • 628
    downloads
  • 50
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Ashutosh Kumar
  2. Litao Xie
  3. Chau My Ta
  4. Antentor J Hinton
  5. Susheel K Gunasekar
  6. Rachel A Minerath
  7. Karen Shen
  8. Joshua M Maurer
  9. Chad E Grueter
  10. E Dale Abel
  11. Gretchen Meyer
  12. Rajan Sah
(2020)
SWELL1 regulates skeletal muscle cell size, intracellular signalling, adiposity and glucose metabolism
eLife 9:e58941.
https://doi.org/10.7554/eLife.58941

Share this article

https://doi.org/10.7554/eLife.58941

Further reading

    1. Cancer Biology
    2. Cell Biology
    Xiangning Bu, Nathanael Ashby ... Inhee Chung
    Research Article

    Cell crowding is a common microenvironmental factor influencing various disease processes, but its role in promoting cell invasiveness remains unclear. This study investigates the biomechanical changes induced by cell crowding, focusing on pro-invasive cell volume reduction in ductal carcinoma in situ (DCIS). Crowding specifically enhanced invasiveness in high-grade DCIS cells through significant volume reduction compared to hyperplasia-mimicking or normal cells. Mass spectrometry revealed that crowding selectively relocated ion channels, including TRPV4, to the plasma membrane in high-grade DCIS cells. TRPV4 inhibition triggered by crowding decreased intracellular calcium levels, reduced cell volume, and increased invasion and motility. During this process, TRPV4 membrane relocation primed the channel for later activation, compensating for calcium loss. Analyses of patient-derived breast cancer tissues confirmed that plasma membrane-associated TRPV4 is specific to high-grade DCIS and indicates the presence of a pro-invasive cell volume reduction mechanotransduction pathway. Hyperosmotic conditions and pharmacologic TRPV4 inhibition mimicked crowding-induced effects, while TRPV4 activation reversed them. Silencing TRPV4 diminished mechanotransduction in high-grade DCIS cells, reducing calcium depletion, volume reduction, and motility. This study uncovers a novel pro-invasive mechanotransduction pathway driven by cell crowding and identifies TRPV4 as a potential biomarker for predicting invasion risk in DCIS patients.

    1. Cell Biology
    Dan Wu, Venkateswararao Eeda ... Weidong Wang
    Research Article

    Overnutrition engenders the expansion of adipose tissue and the accumulation of immune cells, in particular, macrophages, in the adipose tissue, leading to chronic low-grade inflammation and insulin resistance. In obesity, several proinflammatory subpopulations of adipose tissue macrophages (ATMs) identified hitherto include the conventional ‘M1-like’ CD11C-expressing ATM and the newly discovered metabolically activated CD9-expressing ATM; however, the relationship among ATM subpopulations is unclear. The ER stress sensor inositol-requiring enzyme 1α (IRE1α) is activated in the adipocytes and immune cells under obesity. It is unknown whether targeting IRE1α is capable of reversing insulin resistance and obesity and modulating the metabolically activated ATMs. We report that pharmacological inhibition of IRE1α RNase significantly ameliorates insulin resistance and glucose intolerance in male mice with diet-induced obesity. IRE1α inhibition also increases thermogenesis and energy expenditure, and hence protects against high fat diet-induced obesity. Our study shows that the ‘M1-like’ CD11c+ ATMs are largely overlapping with but yet non-identical to CD9+ ATMs in obese white adipose tissue. Notably, IRE1α inhibition diminishes the accumulation of obesity-induced metabolically activated ATMs and ‘M1-like’ ATMs, resulting in the curtailment of adipose inflammation and ensuing reactivation of thermogenesis, without augmentation of the alternatively activated M2 macrophage population. Our findings suggest the potential of targeting IRE1α for the therapeutic treatment of insulin resistance and obesity.